COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP005 trial data in fourth quarter 2024, COMP006 trial top-line data expected mid-2025 Compass announces positive phase 2 COMP360 data in post-traumatic stress disorder (PTSD) Michael Gold to join Compass as Head of R&D Compass enters into additional commercial collaborations, including with Reliant Medical Group, part of Optum Care Cash position of $262.9 million at March 31, 2024 Conference call May 8 at 8:00 a ...

Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed Early and clinically meaningful improvement from baseline in mean CAPS-5 total score (29.5 point reduction at week 12), with change from baseline in mean SDS total score (14.4 point reduction at week 12) 81.8% response (reduction of ≥ 15 points in CAPS-5 score), 63.6% remission (total CAPS-5 ≤ 20) rates at week 4 with 77.3% response and 54.5% remission at week 12 Measures of symptom scores relative ...

公司背景 - Compass Pathways是一家专注于加速患者获得基于证据的创新心理健康治疗的生物技术公司[4] - 公司的核心业务是改善那些患有心理健康挑战且目前治疗无效的人群的生活，正在开发一种新型的牛头酒菌素治疗模式[4] 业绩发布 - 公司将于2024年5月8日发布截至2024年3月31日的第一季度财务业绩，并更新最近的业务发展情况[1] 临床项目 - 公司已经启动了针对治疗难治性抑郁症的COMP360牛头酒菌素治疗的第三阶段临床项目，这是迄今为止规模最大的随机、对照、双盲牛头酒菌素治疗临床项目[5]

文章核心观点 - 该公司与Mindful Health Solutions(MHS)达成研究合作协议,旨在了解如何在不同的医疗服务环境中有效地提供COMP360 psilocybin治疗[1][3][4] - MHS是美国领先的创新行为健康护理提供商之一,专注于为治疗抵抗性抑郁症(TRD)等患者提供先进的干预性治疗选择[2][4] - 双方将就COMP360 psilocybin治疗的潜在交付模式、TRD患者的就诊路径、治疗师培训需求等方面进行深入交流与研究[3] - 该公司此前已与其他医疗机构建立了类似的研究合作关系,旨在更好地了解如何将COMP360 psilocybin治疗推广到患者[4] 公司概况 - 该公司是一家专注于加速患者获得心理健康创新治疗的生物技术公司[5] - 该公司正在开展COMP360 psilocybin治疗的III期临床试验,这是有史以来最大规模的针对治疗抵抗性抑郁症的双盲安慰剂对照试验[6] - 该公司总部位于英国伦敦,在美国纽约和旧金山设有办事处[7] 行业概况 - 目前有数百万美国人患有抑郁症,但现有治疗方法无法有效帮助他们[4] - 该公司致力于开发新的psilocybin治疗模式,其COMP360 psilocybin治疗已获得FDA突破性疗法和英国ILAP指定[5] - 该公司正在开展COMP360 psilocybin治疗的II期临床试验,用于治疗创伤后应激障碍(PTSD)和厌食症[6]

LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Journey Clinical, a leading psychedelic-assisted psychotherapy platform with the largest network of licensed therapists focused on psychedelics in the US, today announced they have entered into a research collaboration agreement to inform the development of a scalable and practical delivery and healthcar ...

COMPASS Pathways plc (NASDAQ:CMPS) Q4 2023 Earnings Conference Call February 29, 2024 8:00 AM ET Company Participants Stephen Schultz - Senior Vice President, Investor Relations Kabir Nath - Chief Executive Officer Mary-Rose Hughes - Interim Financial Officer Teri Loxam - Incoming Chief Financial Officer Dr. Guy Goodwin - Chief Medical Officer Conference Call Participants Patrick Trucchio - H.C. Wainright Charles Duncan - Cantor François Brisebois - Oppenheimer Neena Bitritto-Garg - Deutsche Bank Ritu Baral ...

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights London, UK – February 29, 2024 Highlights: • COMP360 phase 3 pivotal program ongoing; COMP005 trial top-line data now expected in fourth quarter 2024, COMP006 remains on track for top-line data in mid-2025 • Teri Loxam to assume Chief Financial Officer role on March 1, 2024 • Cash position of $220.2 million at December 31, 2023, additional $31.4 million net cash raised to date in first quarter 2024 • Conference call Feb ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ⊠ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) O F THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-39522 COMPASS Pathways plc (Exact name of registrant as specified in its charter) England and Wales Not Applicable (State or ...

微型股投资机会 - 本月有一些微型股值得投资者关注，尽管大盘指数如标普500和纳斯达克表现出强势和弱势迹象，但我相信这些指数仍有很大的上涨空间[1] - 投资者开始关注常被忽视的微型股领域，这些公司拥有创新产品、强大管理团队和引人注目的增长前景[2] - 在接下来的分析中，我们将深入探讨一些有望在未来几个月表现优异的微型股。其中一些是逆势投资，而另一些则更加稳健[3]

公司概况 - Compass Pathways是一家专注于加速患者获得基于证据的心理健康创新的生物技术公司[3] - 公司总部位于伦敦，英国，在美国纽约和旧金山设有办事处[3] 产品与项目 - COMP360被美国食品和药物管理局（FDA）指定为突破性疗法，并在英国获得创新许可和获取途径（ILAP）认定[3] - Compass Pathways正在进行针对治疗难治性抑郁症（TRD）的COMP360哌甲酯研究的第3阶段临床项目[3]